Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-12-31 4:13 pm Purchase | 2024-12-23 | 13G | Avalo Therapeutics, Inc. AVTX | Affinity Asset Advisors LLC | 550,765 5.300% | 550,765 (New Position) | Filing History |
| 2024-12-09 4:14 pm Purchase | 2024-12-02 | 13G | Inozyme Pharma, Inc. INZY | Affinity Asset Advisors LLC | 3,972,318 6.180% | 3,972,318 (New Position) | Filing History |
| 2024-11-13 4:06 pm Purchase | 2024-09-30 | 13G | NextCure, Inc. NXTC | Affinity Asset Advisors LLC | 2,302,598 8.220% | 629,759 (+37.65%) | Filing History |
| 2024-08-14 4:05 pm Purchase | 2024-06-30 | 13G | Climb Bio, Inc. CLYM | Affinity Asset Advisors LLC | 1,813,193 2.700% | 143,193 (+8.57%) | Filing History |
| 2024-06-27 4:47 pm Purchase | 2024-06-20 | 13G | NextCure, Inc. NXTC | Affinity Asset Advisors LLC | 1,672,839 5.980% | 1,672,839 (New Position) | Filing History |
| 2024-05-07 6:01 pm Purchase | 2024-05-01 | 13G | Climb Bio, Inc. CLYM | Affinity Asset Advisors LLC | 1,670,000 6.020% | 1,670,000 (New Position) | Filing History |
| 2024-02-13 4:55 pm Sale | 2023-12-31 | 13G | Vincerx Pharma, Inc. VINC | Affinity Asset Advisors LLC | 0 0.000% | -74,639 (Position Closed) | Filing History |
| 2024-02-13 4:48 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Affinity Asset Advisors LLC | 653,409 1.810% | 653,409 (New Position) | Filing History |
| 2024-02-13 4:45 pm Sale | 2023-12-31 | 13G | Context Therapeutics Inc. CNTX | Affinity Asset Advisors LLC | 328,817 2.060% | -554,837 (-62.79%) | Filing History |
| 2023-07-03 4:20 pm Purchase | 2023-06-22 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Affinity Asset Advisors LLC | 299,080 9.230% | 299,080 (New Position) | Filing History |
| 2023-02-13 4:11 pm Purchase | 2022-12-31 | 13G | Vincerx Pharma, Inc. VINC | Affinity Asset Advisors LLC | 74,639 7.040% | 17,870 (+31.48%) | Filing History |
| 2022-05-09 5:11 pm Purchase | 2022-04-28 | 13G | Context Therapeutics Inc. CNTX | Affinity Asset Advisors LLC | 883,654 5.530% | 883,654 (New Position) | Filing History |
| 2022-02-11 4:13 pm Purchase | 2021-12-31 | 13G | Vincerx Pharma, Inc. VINC | Affinity Asset Advisors LLC | 56,768 5.390% | 2,957 (+5.50%) | Filing History |
| 2021-11-22 2:50 pm Purchase | 2021-11-10 | 13G | Vincerx Pharma, Inc. VINC | Affinity Asset Advisors LLC | 53,811 5.120% | 53,811 (New Position) | Filing History |